AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36349973 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary food and anti-infective treatments
Number of subjects: 1431
Study 34515108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully adjusted Doppler standards
Number of subjects: 4505
Study 34515108 — intervention group
Group type: COMPARATOR
Intervention: GA-only-adjusted standards
Number of subjects: 4505
Study 32767064 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy/cervicopexy (LSC‐Cx)
Number of subjects: 120
Study 32767064 — intervention group
Group type: COMPARATOR
Intervention: Anterior vaginal mesh (AVM)
Number of subjects: 120
Study 32975829 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable gluten sensor (low, medium, and high numbers of single-use capsules)
Number of subjects: 30
Study 36203046 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily (b.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) ophthalmic gel
Number of subjects: 168
Study 36203046 — intervention group
Group type: COMPARATOR
Intervention: Four times daily (q.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) eye drops
Number of subjects: 168
Study 34278611 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL 5-mg infusion
Number of subjects: 60
Study 34278611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35799973 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy
Number of subjects: 200
Study 32286906 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nurse intervention using visual materials
Number of subjects: 220
Study 32286906 — intervention group
Group type: COMPARATOR
Intervention: Brief nurse intervention using verbal descriptions
Number of subjects: 220
Study 33704353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative radiation therapy (A‐RT) at 98 Gy biologically effective dose
Number of subjects: 119
Study 33704353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative radiation therapy (A‐RT)
Number of subjects: 119
Study 32041661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepectoral implant placement
Number of subjects: 70
Study 32041661 — intervention group
Group type: COMPARATOR
Intervention: Subpectoral implant placement
Number of subjects: 70
Study 34014693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy (CBCT)
Number of subjects: 108
Study 34014693 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine
Number of subjects: 108
Study 32379683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot orange essence (2 drops of 3%)
Number of subjects: 60
Study 32379683 — intervention group
Group type: COMPARATOR
Intervention: Odourless grape seed oil (control group, 2 drops)
Number of subjects: 60
Study 35165478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical submucosal debridement using titanium curettes combined with glycine powder air-polishing
Number of subjects: 28
Study 35165478 — intervention group
Group type: COMPARATOR
Intervention: Mechanical submucosal debridement using titanium only (Control)
Number of subjects: 28
Study 32965691 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MAP (90 mm Hg)
Number of subjects: 24
Study 32965691 — intervention group
Group type: COMPARATOR
Intervention: Lower MAP (60 mm Hg)
Number of subjects: 24
Study 34554814 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (text message reminders)
Number of subjects: 0
Study 34554814 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 0
Study 32470217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 43
Study 32470217 — intervention group
Group type: COMPARATOR
Intervention: Mometasone nasal irrigation
Number of subjects: 43
Study 34014490 — intervention group
Group type: EXPERIMENTAL
Intervention: BE-infused digital outreach materials
Number of subjects: 0
Study 34014490 — intervention group
Group type: COMPARATOR
Intervention: Standard outreach materials (implied control)
Number of subjects: 0
Study 32485785 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 26
Study 32485785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 36451139 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing) therapy, 3 to 5 sessions
Number of subjects: 4
Study 35694079 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 75
Study 35694079 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 75
Study 35694079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75
Study 35694079 — intervention group
Group type: COMPARATOR
Intervention: Inhalation groups (Desflurane, Propofol, Sevoflurane)
Number of subjects: 75
Study 34706456 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Cranial Electrotherapy Stimulation (CES) with in-ear electrodes (10 Hz frequency, 500 μA intensity) for 3 weeks, 20 trials at home.
Number of subjects: 0
Study 34706456 — intervention group
Group type: COMPARATOR
Intervention: Sham group (placebo control).
Number of subjects: 0
Study 34706456 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Cranial Electrotherapy Stimulation (CES) with in-ear electrodes.
Number of subjects: 0
Study 36102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma YKL‐40 levels
Number of subjects: 3377
Study 36102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Each SD increase in log-transformed YKL‐40 level
Number of subjects: 3377
Study 36102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding YKL‐40 to a model with conventional risk factors
Number of subjects: 3377
Study 36102255 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL‐40 levels
Number of subjects: 3377
Study 32585039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (7.5 mg/kg body weight)
Number of subjects: 23
Study 32585039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 36136760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bOPV + OCV
Number of subjects: 579
Study 36136760 — intervention group
Group type: COMPARATOR
Intervention: bOPV-only
Number of subjects: 579
Study 36136760 — intervention group
Group type: COMPARATOR
Intervention: OCV-only
Number of subjects: 579
Study 33675631 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA401 100 mg b.i.d.
Number of subjects: 266
Study 33675631 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA401 25 mg b.i.d.
Number of subjects: 266
Study 33675631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative interobserver measurements on pelvic radiographs
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative interobserver measurements on CT images
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative interobserver measurements on pelvic radiographs
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative interobserver measurements on CT images
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraobserver measurements on pelvic radiographs
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraobserver measurements on CT images
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraobserver measurements on pelvic radiographs
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraobserver measurements on CT images
Number of subjects: 60
Study 32769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy measurements
Number of subjects: 60
Study 34112040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy condition (self-disclosure and shared values)
Number of subjects: 0
Study 34112040 — intervention group
Group type: COMPARATOR
Intervention: Information condition (discussing information from an article about climate change)
Number of subjects: 0
Study 32032416 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with concentrated growth factor (CGF)
Number of subjects: 40
Study 32032416 — intervention group
Group type: COMPARATOR
Intervention: No surgery (control group)
Number of subjects: 40
Study 32032416 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with CGF
Number of subjects: 40
Study 35363203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina (TN)
Number of subjects: 612
Study 35363203 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 612
Study 35363203 — intervention group
Group type: COMPARATOR
Intervention: Tuina combined with Physiotherapy (TN + PT)
Number of subjects: 612
Study 35510597 — intervention group
Group type: EXPERIMENTAL
Intervention: Awakening from REM sleep
Number of subjects: 20
Study 35510597 — intervention group
Group type: COMPARATOR
Intervention: Awakening from stage N1/N2 sleep
Number of subjects: 20
Study 34609381 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist user interface for the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)
Number of subjects: 0
Study 34609381 — intervention group
Group type: COMPARATOR
Intervention: DC/TMD diagnostic decision trees (control tool)
Number of subjects: 0
Study 32250530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyo avexitide (exendin 9-39) at ascending doses, administered SC twice daily for 3 days
Number of subjects: 19
Study 32250530 — intervention group
Group type: EXPERIMENTAL
Intervention: Liq avexitide (exendin 9-39) at a fixed dose of 30 mg, administered SC twice daily for 3 days
Number of subjects: 19
Study 35039301 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate ointment (5 times a day)
Number of subjects: 102
Study 35039301 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual oral hygiene guidance only)
Number of subjects: 102
Study 34273797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (MA)
Number of subjects: 62
Study 34273797 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 33543283 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 10
Study 33543283 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS/AE
Number of subjects: 10
Study 33543283 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS/AE
Number of subjects: 10
Study 32299482 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib alone (Control group)
Number of subjects: 106
Study 32299482 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate plus etoricoxib (Experimental group)
Number of subjects: 106
Study 36474794 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention (targeted nutrition, progressive resistance exercise, arthritis self-management support)
Number of subjects: 0
Study 36474794 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention
Number of subjects: 0
Study 36474794 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33392944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral cyclophotocoagulation with MicroPulse® laser (3000 mW)
Number of subjects: 30
Study 33392944 — intervention group
Group type: COMPARATOR
Intervention: Ahmed valve implantation
Number of subjects: 30
Study 33392944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 35765222 — intervention group
Group type: EXPERIMENTAL
Intervention: RT001 (2.88 g/day, increased to 8.64 g/day as tolerated)
Number of subjects: 16
Study 35765222 — intervention group
Group type: EXPERIMENTAL
Intervention: RT001 (5.6 ± 1.6 g/day; dose range, 1.92 to 8.64 g/day)
Number of subjects: 16
Study 35765222 — intervention group
Group type: EXPERIMENTAL
Intervention: RT001
Number of subjects: 16
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing-up milk
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwi
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 33
Study 32648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderberry
Number of subjects: 33
Study 34389633 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg three times daily for 42 days
Number of subjects: 36
Study 34389633 — intervention group
Group type: COMPARATOR
Intervention: Placebo/open-label GSK2982772
Number of subjects: 36
Study 33040948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling added to standard care
Number of subjects: 20
Study 33040948 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 20
Study 34110859 — intervention group
Group type: EXPERIMENTAL
Intervention: Leading questions
Number of subjects: 1182
Study 34110859 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborate leading questions
Number of subjects: 1182
Study 34110859 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctored photographs
Number of subjects: 1182
Study 34110859 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple narratives
Number of subjects: 1182
Study 34110859 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambled narratives
Number of subjects: 1182
Study 34110859 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing word narratives
Number of subjects: 1182
Study 32163323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (CR) when fully rested
Number of subjects: 0
Study 32163323 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reappraisal (CR) after sleep deprivation
Number of subjects: 0
Study 32163323 — intervention group
Group type: COMPARATOR
Intervention: Neural responses to negative images under sleep deprivation
Number of subjects: 0
Study 32163323 — intervention group
Group type: COMPARATOR
Intervention: Negative affect ratings and heart rate deceleration under sleep deprivation
Number of subjects: 0
Study 33823211 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL)
Number of subjects: 204
Study 33823211 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 204
Study 34075199 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum fluorescein tear break-up time (FTBUTmax)
Number of subjects: 147
Study 33357510 — intervention group
Group type: COMPARATOR
Intervention: Intravenous carboplatin (AUC5 or AUC6) and intravenous paclitaxel (175 mg/m2) on day 1 of every 21‐day cycle (control group)
Number of subjects: 779
Study 33357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 2)
Number of subjects: 779
Study 33357510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose‐fractionated carboplatin (AUC2) and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 3)
Number of subjects: 779
Study 32474130 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST)
Number of subjects: 336
Study 32474130 — intervention group
Group type: COMPARATOR
Intervention: 5-session telephone-administered coping effectiveness training (teleCET)
Number of subjects: 336
Study 32186013 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao (JWXY) capsules
Number of subjects: 210
Study 32186013 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 210
Study 35129242 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV clinic‐based extended‐release naltrexone (XR‐NTX; n = 55)
Number of subjects: 114
Study 35129242 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n = 59)
Number of subjects: 114
Study 35129242 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV clinic‐based extended‐release naltrexone (XR‐NTX)
Number of subjects: 114
Study 35129242 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 114
Study 35129242 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV clinic‐based extended‐release naltrexone (XR‐NTX) among those initiating medication
Number of subjects: 114
Study 35129242 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) among those initiating medication
Number of subjects: 114
Study 34486272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoginal vaginal probiotic after standard antibacterial therapy
Number of subjects: 120
Study 34486272 — intervention group
Group type: COMPARATOR
Intervention: Standard antibacterial therapy
Number of subjects: 120
Study 32273244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep improvement intervention (3 weekly sessions lasting 90 to 120 minutes)
Number of subjects: 120
Study 32273244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep improvement intervention
Number of subjects: 120
Study 35627446 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low impact aerobics program supplemented by one EMG biofeedback session and pelvic floor muscle training
Number of subjects: 42
Study 35627446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 34081045 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 24
Study 34081045 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 24
Study 34081045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 24
Study 32847917 — intervention group
Group type: EXPERIMENTAL
Intervention: Xueshuantong injection (lyophilised) (XST)
Number of subjects: 1200
Study 32847917 — intervention group
Group type: COMPARATOR
Intervention: 1/20th dose of Xueshuantong injection (lyophilised) (Control)
Number of subjects: 1200
Study 35252270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 369
Study 35252270 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 369
Study 32444250 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 2.5 mg/kg/day with oral curcumin 3 g/day
Number of subjects: 48
Study 32444250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34432204 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangfuyan Capsules (4 capsules, 3 times daily for 12 weeks)
Number of subjects: 240
Study 34432204 — intervention group
Group type: COMPARATOR
Intervention: Gongyanping Capsules (control group, 4 capsules, 3 times daily for 12 weeks)
Number of subjects: 240
Study 36361252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 36361252 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 33187506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate advance care plan group
Number of subjects: 36
Study 33187506 — intervention group
Group type: COMPARATOR
Intervention: Deferred advance care plan group
Number of subjects: 36
Study 33966118 — intervention group
Group type: EXPERIMENTAL
Intervention: metreleptin treatment
Number of subjects: 1
Study 32723072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention with automated assessment and behavior change calls for patients and structured feedback for caregivers.
Number of subjects: 0
Study 32581041 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Number of subjects: 1
Study 32581041 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and docetaxel (first-line treatment)
Number of subjects: 1
Study 36459262 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse imaging incubator (TLI) (EmbryoScope)
Number of subjects: 9
Study 36459262 — intervention group
Group type: COMPARATOR
Intervention: Standard incubators (SI, G185 K-System)
Number of subjects: 9
Study 36459262 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse imaging incubator (TLI)
Number of subjects: 9
Study 36459262 — intervention group
Group type: COMPARATOR
Intervention: Standard incubators (SI)
Number of subjects: 9
Study 36459262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TLI and SI
Number of subjects: 9
Study 33714741 — intervention group
Group type: COMPARATOR
Intervention: High burden of HF signs and symptoms (?3)
Number of subjects: 4725
Study 36154603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg tablet 90 minutes before surgery
Number of subjects: 92
Study 36154603 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 150 µg tablet 90 minutes before surgery
Number of subjects: 92
Study 36154603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 34077619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) applied via microneedling
Number of subjects: 20
Study 34077619 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied via microneedling
Number of subjects: 20
Study 32982212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine 0.75 to 6mg twice daily
Number of subjects: 100
Study 32982212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine 6mg
Number of subjects: 100
Study 35387855 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person HOBSCOTCH (H-IP)
Number of subjects: 85
Study 35387855 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual HOBSCOTCH (H-V)
Number of subjects: 85
Study 35387855 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 85
Study 33120137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (N = 67)
Number of subjects: 125
Study 33120137 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction group therapy (N = 58)
Number of subjects: 125
Study 36072375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) exercise for 48 weeks
Number of subjects: 0